Search Results - "Mennitto, Alessia"

Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives by Vernieri, Claudio, Milano, Monica, Brambilla, Marta, Mennitto, Alessia, Maggi, Claudia, Cona, Maria Silvia, Prisciandaro, Michele, Fabbroni, Chiara, Celio, Luigi, Mariani, Gabriella, Bianchi, Giulia Valeria, Capri, Giuseppe, de Braud, Filippo

“…[Display omitted] HER2-positive breast cancer (HER2 + BC) represents 15–20% of all BCs. In the last two decades, the introduction of monoclonal antibodies…”
Get full text

Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer by Pietrantonio, Filippo, Vernieri, Claudio, Siravegna, Giulia, Mennitto, Alessia, Berenato, Rosa, Perrone, Federica, Gloghini, Annunziata, Tamborini, Elena, Lonardi, Sara, Morano, Federica, Picciani, Benedetta, Busico, Adele, Volpi, Chiara Costanza, Martinetti, Antonia, Battaglin, Francesca, Bossi, Ilaria, Pellegrinelli, Alessio, Milione, Massimo, Cremolini, Chiara, Di Bartolomeo, Maria, Bardelli, Alberto, de Braud, Filippo

“…Even if wild-type and -negative metastatic colorectal cancer (mCRC) patients frequently respond to anti-EGFR mAbs, acquired resistance almost invariably…”
Get full text

Immune-checkpoint inhibitors and metastatic prostate cancer therapy: Learning by making mistakes by Claps, Mélanie, Mennitto, Alessia, Guadalupi, Valentina, Sepe, Pierangela, Stellato, Marco, Zattarin, Emma, Gillessen, Sommer Silke, Sternberg, Cora N., Berruti, Alfredo, De Braud, Filippo Guglielmo Maria, Verzoni, Elena, Procopio, Giuseppe

“…•Metastatic castration resistant prostate cancer express PD-L1 in 32% of cases.•CDK12-mutations could predict response to PD-1/PD-L1 inhibitors.•Combinations…”
Get full text

Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer by Raimondi, Alessandra, Sepe, Pierangela, Zattarin, Emma, Mennitto, Alessia, Stellato, Marco, Claps, Melanie, Guadalupi, Valentina, Verzoni, Elena, de Braud, Filippo, Procopio, Giuseppe

“…In the last decades, the therapeutic decision-making approach to metastatic renal cell cancer (mRCC) has dramatically changed thanks to the introduction in the…”
Get full text

Untargeted lipidomics reveal association of elevated plasma C18 ceramide levels with reduced survival in metastatic castration-resistant prostate cancer patients by Cattrini, Carlo, Manfredi, Marcello, Barboro, Paola, Ghirimoldi, Marco, Mennitto, Alessia, Martini, Veronica, Battioni, Alessio, Le Van, Marco, Gobbato, Simone, Branni, Carmen, Ayed, Rahma Ben, Pinato, David James, Catalano, Fabio, Zanardi, Elisa, Boccardo, Francesco, Gennari, Alessandra

“…Emerging evidence highlights the potential prognostic relevance of circulating lipids in metastatic castration-resistant prostate cancer (mCRPC), with a…”
Get full text

Is there a preferred first-line therapy for metastatic renal cell carcinoma? A network meta-analysis by Cattrini, Carlo, Messina, Carlo, Airoldi, Chiara, Buti, Sebastiano, Roviello, Giandomenico, Mennitto, Alessia, Caffo, Orazio, Gennari, Alessandra, Bersanelli, Melissa

“…Background: In recent years, new therapeutic combinations based on immunotherapy provided significant benefits as a first-line treatment for patients with…”
Get full text

Current Understanding of Urachal Adenocarcinoma and Management Strategy by Claps, Mélanie, Stellato, Marco, Zattarin, Emma, Mennitto, Alessia, Sepe, Pierangela, Guadalupi, Valentina, Mennitto, Roberta, de Braud, Filippo G.M., Verzoni, Elena, Procopio, Giuseppe

“…Purpose of Review The aim of this review is to sum up the state of the art of urachal carcinoma (UC) in order to easily guide clinicians. Recent Findings UC is…”
Get full text

Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study by Rizzo, Mimma, Soares, Andrey, Grande, Enrique, Bamias, Aristotelis, Kopp, Ray Manneh, Lenci, Edoardo, Buttner, Thomas, Salah, Samer, Grillone, Francesco, de Carvalho, Icaro Thiago, Tapia, Jose Carlos, Gucciardino, Calogero, Pinto, Alvaro, Mennitto, Alessia, Abahssain, Halima, Rescigno, Pasquale, Myint, Zin, Takeshita, Hideki, Spinelli, Gian Paolo, Popovic, Lazar, Vitale, Maria Giuseppa, Fiala, Ondrej, Giannatempo, Patrizia, Zakopoulou, Roubini, Carrozza, Francesco, Massari, Francesco, Monteiro, Fernando Sabino Marques, Pace, Maria Paola, Giannini, Massimo, Roviello, Giandomenico, Porta, Camillo, Battelli, Nicola, Kanesvaran, Ravindran, Santoni, Matteo

“…The addition of metastasis-directed radiotherapy (MDRT) to immunotherapy in patients with advanced urothelial carcinoma (aUC) has shown promising results. We…”
Get full text

Clinical outcome of renal cancer patients who early interrupted immunotherapy due to serious immune-related adverse events. Meet-Uro 13 trial on behalf of the MeetUro investigators by Stellato, Marco, Procopio, Giuseppe, De Giorgi, Ugo, Maruzzo, Marco, Bimbatti, Davide, Mennitto, Alessia, Sbrana, Andrea, Roviello, Giandomenico, Casadei, Chiara, Sepe, Pierangela, Pignata, Sandro, Santini, Daniele

“…Abstract Background Severe immune-related Adverse Events (irAEs) develop in 10–27% of patients treated with Immune-Oncology (IO) [Powles (Lancet 391:748–757,…”
Get full text

Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a) by Stellato, Marco, Buti, Sebastiano, Maruzzo, Marco, Bersanelli, Melissa, Pierantoni, Francesco, De Giorgi, Ugo, Di Napoli, Marilena, Iacovelli, Roberto, Vitale, Maria Giuseppa, Ermacora, Paola, Malgeri, Andrea, Maiorano, Brigida Anna, Prati, Veronica, Mennitto, Alessia, Cavo, Alessia, Santoni, Matteo, Carella, Claudia, Fratino, Lucia, Procopio, Giuseppe, Verzoni, Elena, Santini, Daniele

“…Non-clear cell renal cell carcinoma (nccRCC) represents a heterogeneous histological group which is 20-25% of those with renal cell carcinoma (RCC). Patients…”
Get full text

The role of mean corpuscular volume and red cell distribution width in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: the MARECAP retrospective study by Tommasi, Chiara, Scartabellati, Giulia, Giannarelli, Diana, Giorgi, Ugo De, Brighi, Nicole, Fornarini, Giuseppe, Rebuzzi, Sara Elena, Puglisi, Silvia, Caffo, Orazio, Kinspergher, Stefania, Mennitto, Alessia, Cattrini, Carlo, Santoni, Matteo, Verzoni, Elena, Rametta, Alessandro, Stellato, Marco, Malgeri, Andrea, Roviello, Giandomenico, Brunelli, Matteo, Buti, Sebastiano

“…Background: Tyrosine-kinase inhibitors (TKIs) and immunotherapy represent the backbone treatment for metastatic renal cell carcinoma (mRCC) patients. The aim…”
Get full text

Insulin/IGF Axis in Breast Cancer: Clinical Evidence and Translational Insights by Biello, Federica, Platini, Francesca, D'Avanzo, Francesca, Cattrini, Carlo, Mennitto, Alessia, Genestroni, Silvia, Martini, Veronica, Marzullo, Paolo, Aimaretti, Gianluca, Gennari, Alessandra

“…Breast cancer (BC) is the most common neoplasm in women. Many clinical and preclinical studies investigated the possible relationship between host metabolism…”
Get full text

Nivolumab in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience by Mennitto, Alessia, Grassi, Paolo, Ratta, Raffaele, Verzoni, Elena, Prisciandaro, Michele, Procopio, Giuseppe

“…Renal cell carcinoma (RCC) is considered an immunogenic tumor with a prominent dysfunctional immune cell infiltrate, unable to control tumor growth…”
Get full text

Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials by Cremolini, Chiara, Milione, Massimo, Marmorino, Federica, Morano, Federica, Zucchelli, Gemma, Mennitto, Alessia, Prisciandaro, Michele, Lonardi, Sara, Pellegrinelli, Alessio, Rossini, Daniele, Bergamo, Francesca, Aprile, Giuseppe, Urbani, Lucio, Morelli, Luca, Schirripa, Marta, Cardellino, Giovanni Gerardo, Fassan, Matteo, Fontanini, Gabriella, de Braud, Filippo, Mazzaferro, Vincenzo, Falcone, Alfredo, Pietrantonio, Filippo

“…Background Many factors, including histopathologic parameters, seem to influence the prognosis of patients undergoing resection of colorectal cancer liver…”
Get full text

Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism? by Roviello, Giandomenico, Buti, Sebastiano, Cattrini, Carlo, Mennitto, Alessia, Messina, Carlo, Airoldi, Chiara, Vannini, Gianmarco, Bersanelli, Melissa

Get full text

Everolimus treatment for neuroendocrine tumors: latest results and clinical potential by Pusceddu, Sara, Verzoni, Elena, Prinzi, Natialie, Mennitto, Alessia, Femia, Daniela, Grassi, Paolo, Concas, Laura, Vernieri, Claudio, Lo Russo, Giuseppe, Procopio, Giuseppe

“…Neuroendocrine tumors (NETs) are a heterogeneous class of diseases characterized by challenging management. Preclinical evidence shows that the PI3K/AKT/mTOR…”
Get full text

Integrating Red Blood Cell Features and Hemoglobin Levels in Metastatic Renal Cell Carcinoma Patients Treated with Pazopanib or Cabozantinib: An Easily Exploitable Prognostic Score by Mazzaschi, Giulia, Lazzarin, Alessandro, Santoni, Matteo, Trentini, Francesca, Giorgi, Ugo De, Brighi, Nicole, Tommasi, Chiara, Puglisi, Silvia, Caffo, Orazio, Kinspergher, Stefania, Mennitto, Alessia, Cattrini, Carlo, Verzoni, Elena, Rametta, Alessandro, Stellato, Marco, Malgeri, Andrea, Roviello, Giandomenico, Silini, Enrico Maria, Rescigno, Pasquale, Rebuzzi, Sara Elena, Fornarini, Giuseppe, Quaini, Federico, Giudice, Giulia Claire, Banna, Giuseppe Luigi, Buti, Sebastiano

“…BACKGROUNDThe advent of immune checkpoint inhibitors (ICIs) has revolutionized the metastatic renal cell carcinoma (mRCC) therapeutic landscape. Nevertheless,…”
Get full text

A phase II study evaluating the efficacy of enzalutamide and the role of liquid biopsy for evaluation of ARv7 in mCRPC patients with measurable metastases including visceral disease (Excalibur study) by Sepe, Pierangela, Procopio, Giuseppe, Pircher, Chiara Carlotta, Basso, Umberto, Caffo, Orazio, Cappelletti, Vera, Claps, Melanie, De Giorgi, Ugo, Fratino, Lucia, Guadalupi, Valentina, Miodini, Patrizia, De Marco, Cinzia, Perrucci, Bruno, Mennitto, Alessia, Santini, Daniele, Spina, Francesco, Stellato, Marco, de Braud, Filippo, Verzoni, Elena

“…Up to 30% of patients with metastatic castration-resistant prostate cancer (mCRPC) develop visceral metastases, which are associated with a poor prognosis…”
Get full text

Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma? by Grassi, Paolo, Verzoni, Elena, Ratta, Raffaele, Porcu, Luca, Prisciandaro, Michele, Mennitto, Alessia, Calareso, Giuseppina, de Braud, Filippo, Procopio, Giuseppe

“…Background Pazopanib is a standard treatment for metastatic renal cell carcinoma (mRCC), and 800 mg/daily is considered the optimal dose. However, some…”
Get full text

Comments on “Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5‐year follow‐up results from the STAMPEDE randomised trial (NCT00268476)” by Cattrini, Carlo, Messina, Carlo, Mennitto, Alessia, Di Maio, Massimo, Gennari, Alessandra, Olmos, David

Get full text